» Articles » PMID: 33441701

Interferon-γ Enhances the Therapeutic Effect of Mesenchymal Stem Cells on Experimental Renal Fibrosis

Overview
Journal Sci Rep
Specialty Science
Date 2021 Jan 14
PMID 33441701
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Mesenchymal stem cells (MSCs) administered for therapeutic purposes can be activated by interferon-γ (IFN-γ) secreted from natural killer cells in injured tissues and exert anti-inflammatory effects. These processes require a substantial period of time, leading to a delayed onset of MSCs' therapeutic effects. In this study, we investigated whether pretreatment with IFN-γ could potentiate the anti-fibrotic ability of MSCs in rats with ischemia-reperfusion injury (IRI) and unilateral ureter obstruction. Administration of MSCs treated with IFN-γ strongly reduced infiltration of inflammatory cells and ameliorated interstitial fibrosis compared with control MSCs without IFN-γ treatment. In addition, conditioned medium obtained from IFN-γ-treated MSCs decreased fibrotic changes in cultured cells induced by transforming growth factor-β1 more efficiently than that from control MSCs. Most notably, secretion of prostaglandin E2 from MSCs was significantly increased by treatment with IFN-γ. Increased prostaglandin E2 in conditioned medium obtained from IFN-γ-treated MSCs induced polarization of immunosuppressive CD163 and CD206-positive macrophages. In addition, knockdown of prostaglandin E synthase weakened the anti-fibrotic effects of MSCs treated with IFN-γ in IRI rats, suggesting the involvement of prostaglandin E2 in the beneficial effects of IFN-γ. Administration of MSCs treated with IFN-γ might represent a promising therapy to prevent the progression of renal fibrosis.

Citing Articles

Association of uric acid to high-density lipoprotein cholesterol ratio with the presence or absence of hypertensive kidney function: results from the China Health and Retirement Longitudinal Study (CHARLS).

Li S, Liu Z, Lu C BMC Nephrol. 2025; 26(1):123.

PMID: 40050799 PMC: 11884189. DOI: 10.1186/s12882-024-03939-7.


Adipose-derived stem cells attenuate rheumatoid arthritis by restoring CXCR1 synovial lining macrophage barrier.

Wang L, Hao M, Xu Y, Wang Z, Xie H, Zhang B Stem Cell Res Ther. 2025; 16(1):111.

PMID: 40038808 PMC: 11881422. DOI: 10.1186/s13287-025-04144-5.


INF-γ/TGF-β1-primed umbilical cord mesenchymal stem cells boost the T-lymphocytes activity: Modulation of CD25 expression and IL-6 secretion.

Almaeen A, Saad-Eldien H, Gabr H Int J Immunopathol Pharmacol. 2025; 39:3946320251315007.

PMID: 39921228 PMC: 11806471. DOI: 10.1177/03946320251315007.


Alginate-polylysine-alginate (APA) microencapsulated transgenic human amniotic epithelial cells ameliorate fibrosis in hypertrophic scars.

Su L, Jia Y, Li Y, Shi J Inflamm Res. 2025; 74(1):22.

PMID: 39862302 DOI: 10.1007/s00011-025-02001-y.


Regulation of Colonic Inflammation and Macrophage Homeostasis of IFN-γ-Primed Canine AMSCs in Experimental Colitis in Mice.

Jo C, Lee S, Son Y, Lee W, Choe Y, Lee H Animals (Basel). 2024; 14(22).

PMID: 39595338 PMC: 11591378. DOI: 10.3390/ani14223283.


References
1.
English K . Mechanisms of mesenchymal stromal cell immunomodulation. Immunol Cell Biol. 2012; 91(1):19-26. DOI: 10.1038/icb.2012.56. View

2.
Lee S, Kalluri R . Mechanistic connection between inflammation and fibrosis. Kidney Int Suppl. 2010; (119):S22-6. PMC: 4067095. DOI: 10.1038/ki.2010.418. View

3.
Luan B, Yoon Y, Le Lay J, Kaestner K, Hedrick S, Montminy M . CREB pathway links PGE2 signaling with macrophage polarization. Proc Natl Acad Sci U S A. 2015; 112(51):15642-7. PMC: 4697393. DOI: 10.1073/pnas.1519644112. View

4.
Matsui F, Babitz S, Rhee A, Hile K, Zhang H, Meldrum K . Mesenchymal stem cells protect against obstruction-induced renal fibrosis by decreasing STAT3 activation and STAT3-dependent MMP-9 production. Am J Physiol Renal Physiol. 2016; 312(1):F25-F32. PMC: 5283885. DOI: 10.1152/ajprenal.00311.2016. View

5.
Jin L, Deng Z, Zhang J, Yang C, Liu J, Han W . Mesenchymal stem cells promote type 2 macrophage polarization to ameliorate the myocardial injury caused by diabetic cardiomyopathy. J Transl Med. 2019; 17(1):251. PMC: 6683374. DOI: 10.1186/s12967-019-1999-8. View